Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05361694 · ClinicalTrials.gov registry record
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
A clinical trial of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by University of Miami.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05361694: Recruiting study of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by University of Miami.
NCT05361694 is a study of Multiple Myeloma and Smoldering Multiple Myeloma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 1,000 participants, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05361694, a study of Multiple Myeloma and Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
Primary Outcome
The rate of progression to active multiple myeloma in participants with tumors with and without myeloma defining genomic events as evaluated by treating physician via clinical assessments (including low-input DNA whole-genome sequencing)
Conditions Studied
Study Locations (1)
Florida
- University of Miami Hospitals - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2027-07-01 |
What NCT05361694 shows while recruiting
NCT05361694 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 544-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% higher).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT05361694 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05361694 about?
NCT05361694 is a clinical study titled "Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions". The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
What is the current status of trial NCT05361694?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-04-12. Estimated completion is 2027-07-01.
What conditions does trial NCT05361694 study?
This clinical trial studies the following conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.
Who is sponsoring clinical trial NCT05361694?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05361694 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05361694's enrollment target sits among peer trials
1,000 21st of 438 higher than 417 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI